PROTAC CG167
PROTAC CG167 is a selective and potent CypA PROTAC degrader. PROTAC CG167 degrades CypA in a dose-dependent manner (Jurkat: DC50: 123 nM) . PROTAC CG167 can inhibit HIV-1 and HCV and exhibits antiviral activity[1]. (Pink: CypA Ligand (HY-170997) ; Black: Linker (HY-W123015) ; Blue: E3 Ligase Ligand (HY-112078) )
Product Specifications
UNSPSC
12352005
Target
Cyclophilin; HCV; HIV; PROTACs
Related Pathways
Anti-infection; Immunology/Inflammation; PROTAC
Field of Research
Infection
Smiles
CC1=C(C2=CC=C(C=C2)[C@@H](NC([C@@H]3C[C@H](CN3C([C@@H](NC(CCCCCN4N=NC(CCC[C@@H](OC([C@H]5NN(CCC5)C([C@H](C)NC([C@@H](NC(C/C=C/6)=O)CC7=CC=C(C=C7)[N+]([O-])=O)=O)=O)=O)C8=CC=C9C=CC6=CC9=N8)=C4)=O)C(C)(C)C)=O)O)=O)C)SC=N1
Molecular Formula
C65H79N13O11S
Molecular Weight
1250.47
References & Citations
[1]Newton LS, et al. Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV. Nat Commun. 2025 Feb 10;16 (1) :1484.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cyclophilin A; HIV-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7100427 Inquire
Recombinant Schizosaccharomyces pombe Uncharacterized rhomboid protein C19B12.06c (SPAC19B12.06c), partial
Ask
View Details